| Literature DB >> 28602063 |
Ji-Won Hwang1, Seung Woo Park1, Eun Jeong Cho2, Ga Yeon Lee1, Eun Kyoung Kim1, Sung-A Chang1, Sung-Ji Park1, Sang-Chol Lee1, Cheol-In Kang3, Doo Ryeon Chung3, Kyong Ran Peck3, Jae-Hoon Song3.
Abstract
BACKGROUND/AIMS: The aim of our study was to compare the characteristics of nosocomial infective endocarditis (NIE) with community-acquired infective endocarditis (CIE) and to determine independent risk factors for in-hospital death.Entities:
Keywords: Clinical risk factors; Nosocomial infective endocarditis; Risk factors for in-hospital death
Mesh:
Year: 2017 PMID: 28602063 PMCID: PMC5768539 DOI: 10.3904/kjim.2016.106
Source DB: PubMed Journal: Korean J Intern Med ISSN: 1226-3303 Impact factor: 2.884
Figure 1.Number of patients with nosocomial infective endocarditis (NIE) and community-acquired infective endocarditis (CIE) from 2000 to 2014 in 5-year intervals.
Baseline clinical characteristics and clinical outcomes of NIE compared with CIE
| Characteristic | CIE (n = 439) | NIE (n = 121) | |
|---|---|---|---|
| Age, yr | 51.30 ± 18.01 | 59.76 ± 14.87 | < 0.001 |
| Male sex | 281 (64.0) | 64 (52.9) | 0.027 |
| Definite infective endocarditis | 312 (71.1) | 94 (77.7) | 0.170 |
| Underlying medical disease | |||
| Liver cirrhosis | 14 (3.2) | 13 (10.7) | 0.002 |
| Alcoholism | 8 (1.8) | 4 (3.3) | 0.300 |
| Diabetes mellitus | 32 (7.3) | 16 (13.2) | 0.045 |
| Chemotherapy | 16 (3.6) | 35 (28.9) | < 0.001 |
| Malignancy | 32 (7.3) | 52 (43.0) | < 0.001 |
| Chronic kidney disease | 22 (5.0) | 20 (16.5) | < 0.001 |
| Hemodialysis | 15 (3.4) | 19 (15.7) | < 0.001 |
| Solid organ transplantation | 1 (0.2) | 1 (0.8) | 0.390 |
| Coronary artery disease | 13 (3.0) | 7 (5.8) | 0.160 |
| Rheumatologic disease | 4 (0.9) | 2 (1.7) | 0.620 |
| Cerebrovascular accident | 13 (3.0) | 2 (1.7) | 0.750 |
| Cardiomyopathy | 5 (1.1) | 1 (0.8) | 1.000 |
| Recurrent infection (biliary, urinary) | 4 (0.9) | 1 (0.8) | 1.000 |
| Other site abscess | 11 (2.5) | 4 (3.3) | 0.540 |
| COPD & ILD | 5 (1.1) | 2 (1.7) | 0.650 |
| Tuberculosis | 15 (3.4) | 3 (2.5) | 0.780 |
| Vascular disease (vasculitis) | 3 (0.7) | 1 (0.8) | 1.000 |
| Underlying cardiac condition | |||
| Congenital heart disease | 95 (21.6) | 5 (4.1) | < 0.001 |
| Prosthetic valve | 84 (19.1) | 17 (14.0) | 0.230 |
| Native valve | 329 (74.9) | 102 (84.3) | 0.038 |
| Central intravenous catheter | 9 (2.1) | 40 (33.1) | < 0.001 |
| Past history of infective endocarditis | 31 (7.1) | 3 (3.3) | 0.200 |
| Predisposing manipulation | |||
| Acupuncture or articular injection | 17 (3.9) | 0 | 0.031 |
| Dental manipulation | 26 (5.9) | 0 | 0.002 |
| Endoscopy with procedure | 1 (0.2) | 4 (3.3) | 0.009 |
| TACE or liver biopsy | 2 (0.5) | 2 (1.7) | 0.210 |
| Genitourinary tract manipulation | 2 (0.5) | 4 (3.3) | 0.022 |
| Orthopedic prosthesis | 1 (0.2) | 2 (1.7) | 0.120 |
| Perivertebral area procedure | 2 (0.5) | 2 (1.7) | 0.210 |
| Intracardiac device (PPM, ICD) | 1 (0.2) | 1 (0.8) | 0.390 |
| Echocardiographic finding | |||
| Transesophageal echocardiogram | 342 (77.9) | 75 (62.0) | < 0.001 |
| Vegetation | |||
| Mitral valve | 258 (58.8) | 57 (47.1) | 0.023 |
| Aortic valve | 163 (37.1) | 48 (39.7) | 0.670 |
| Tricuspid valve | 30 (6.8) | 12 (9.9) | 0.250 |
| Pulmonary valve | 17 (3.9) | 1 (0.8) | 0.140 |
| Right ventricle | 15 (3.4) | 1 (0.8) | 0.210 |
| Right atrium | 7 (1.6) | 8 (6.6) | 0.006 |
| Other site | 22 (5.0) | 6 (5.0) | 1.000 |
| Significant valvular regurgitation | 214 (48.7) | 40 (33.1) | 0.003 |
| Large vegetation (> 2 cm) | 34 (7.7) | 10 (8.3) | 0.750 |
| Perivalvular abscess | 60 (13.7) | 15 (12.4) | 0.770 |
| Perforation | 36 (8.2) | 7 (5.8) | 0.450 |
| Causative organism | |||
| Viridans group streptococci | 128 (29.2) | 8 (6.6) | < 0.001 |
| | |||
| Methicillin-sensitive | 63 (14.4) | 19 (15.7) | 0.770 |
| Methicillin-resistant | 22 (5.0) | 28 (23.1) | < 0.001 |
| | 31 (7.1) | 15 (12.4) | 0.060 |
| Coagulase-negative | 19 (4.3) | 11 (9.1) | 0.060 |
| HACEK | 7 (1.6) | 0 | 0.360 |
| Fungus | 2 (0.5) | 6 (5.0) | 0.002 |
| Other bacteria | 55 (12.5) | 20 (16.5) | 0.290 |
| Culture negative infective endocarditis | 129 (29.4) | 16 (13.2) | < 0.001 |
| Clinical outcomes | |||
| In-hospital death | 26 (5.9) | 33 (27.3) | < 0.001 |
| Cardiac surgery | 298 (67.9) | 46 (38.0) | < 0.001 |
| On indication of cardiac surgery (but not done) | 41 (9.3) | 29 (24.0) | < 0.001 |
| Embolic event | 157 (35.8) | 48 (39.7) | 0.460 |
| Brain | 118 (26.9) | 34 (28.1) | 0.820 |
| Kidney | 14 (3.2) | 5 (4.1) | 0.580 |
| Spleen | 21 (4.8) | 6 (5.0) | 1.000 |
| Lung | 18 (4.1) | 7 (5.8) | 0.460 |
| Extremities | 14 (3.2) | 6 (5.0) | 0.410 |
| Liver | 2 (0.5) | 1 (0.8) | 0.520 |
| Eye (retina) | 6 (1.4) | 2 (1.7) | 0.690 |
| Mycotic aneurysm | 20 (4.5) | 5 (4.1) | 1.000 |
| Duration of hospitalization, day | 35.80 ± 21.70 | 47.33 ± 37.59 | < 0.001 |
Values are presented as mean ± SD or number (%).
NIE, nosocomial infective endocarditis; CIE, community-acquired infective endocarditis; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; TACE, transcatheter arterial chemoembolization; PPM, permanent pacemaker; ICD, implantable cardioverter defibrillator; HACEK, Haemophilus parainfluenzae, Haemophilus aphrophilus, Aggregatibacter actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae.
Univariate and multiple analysis of clinical factors associated with nosocomial infective endocarditis
| Variable | Crude | Adjusted | ||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI)[ | |||
| Age | 1.03 (1.02–1.04) | < 0.001 | 1.02 (1.001–1.04) | 0.006 |
| Male sex | 1.58 (1.06–2.38) | 0.027 | 1.43 (0.86–2.38) | 0.170 |
| Liver cirrhosis | 3.65 (1.67–8.00) | 0.001 | 4.57 (1.86–11.21) | 0.001 |
| Diabetes mellitus | 1.94 (1.03–3.67) | 0.042 | 1.47 (0.67–3.25) | 0.340 |
| Chemotherapy | 10.76 (5.70–20.31) | < 0.001 | 5.03 (2.29–11.06) | < 0.001 |
| Central intravenous catheter | 23.59 (11.0 –50.50) | < 0.001 | 10.18 (4.21–24.62) | < 0.001 |
| Hemodialysis | 5.27 (2.59–10.72) | < 0.001 | 2.58 (1.02–6.53) | 0.046 |
| Endoscopy with procedure | 14.97 (1.66–135.25) | 0.016 | 10.53 (0.98–13.54) | 0.052 |
| Genitourinary tract manipulation | 7.47 (1.35–41.59) | 0.021 | 11.22 (1.84–68.36) | 0.009 |
OR, odds ratio; CI, confidence interval.
Estimated by multiple linear regression analysis of the variables indicated in the table.
Clinical characteristics in dead patients compared with survived patient for the group of NIE and CIE by univariate analysis
| Characteristic | NIE | CIE | ||||
|---|---|---|---|---|---|---|
| Survived (n = 88) | Died (n = 33) | Survived (n = 413) | Died (n = 26) | |||
| Age, yr | 58.08 ± 15.72 | 64.24 ± 11.36 | 0.020 | 50.34 ± 17.62 | 66.54 ± 17.65 | < 0.001 |
| Male sex | 52 (59.1) | 12 (36.4) | 0.040 | 264 (63.9) | 17 (65.4) | 1.000 |
| Underlying medical disease | ||||||
| Liver cirrhosis | 9 (10.2) | 4 (12.1) | 0.750 | 12 (2.9) | 2 (7.7) | 0.200 |
| Alcoholism | 4 (4.5) | 0 | 0.570 | 8 (1.9) | 0 | 1.000 |
| Diabetes mellitus | 14 (15.9) | 2 (6.1) | 0.230 | 31 (7.5) | 1 (3.8) | 0.710 |
| Chemotherapy | 20 (22.7) | 15 (45.5) | 0.023 | 15 (3.6) | 1 (3.8) | 1.000 |
| Malignancy | 32 (36.4) | 20 (60.6) | 0.023 | 28 (6.8) | 4 (15.4) | 0.110 |
| Chronic kidney disease | 18 (20.5) | 2 (6.1) | 0.100 | 19 (4.6) | 3 (11.5) | 0.130 |
| Hemodialysis | 17 (19.3) | 2 (6.1) | 0.100 | 13 (3.1) | 2 (7.7) | 0.220 |
| Solid organ transplantation | 0 | 1 (3.0) | 0.270 | 1 (0.2) | 0 | 1.000 |
| Coronary artery disease | 6 (6.8) | 1 (3.0) | 0.670 | 12 (2.9) | 1 (3.8) | 0.550 |
| Rheumatologic disease | 1 (1.1) | 1 (3.0) | 1.000 | 4 (1.0) | 0 | 1.000 |
| Cerebrovascular accident | 1 (1.1) | 1 (3.0) | 1.000 | 13 (3.1) | 0 | 1.000 |
| Cardiomyopathy | 1 (1.1) | 0 | 1.000 | 4 (1.0) | 1 (3.8) | 0.260 |
| Recurrent infection (biliary, urinary) | 1 (1.1) | 0 | 1.000 | 3 (0.7) | 1 (3.8) | 0.220 |
| Other site abscess | 4 (4.5) | 0 | 0.570 | 9 (2.2) | 2 (7.7) | 0.130 |
| COPD & ILD | 0 | 2 (6.1) | 0.070 | 5 (1.2) | 0 | 1.000 |
| Tuberculosis | 3 (3.4) | 0 | 0.560 | 15 (3.6) | 0 | 1.000 |
| Vascular disease (vasculitis) | 1 (1.1) | 0 | 1.000 | 3 (0.7) | 0 | 1.000 |
| Underlying cardiac condition | ||||||
| Congenital heart disease | 4 (4.5) | 1 (3.0) | 1.000 | 95 (23.0) | 0 | 0.002 |
| Prosthetic valve | 12 (13.6) | 5 (15.2) | 0.780 | 76 (18.4) | 8 (30.8) | 0.130 |
| Native valve | 15 (17.0) | 4 (12.1) | 0.590 | 308 (74.6) | 21 (80.8) | 0.640 |
| On indication of cardiac surgery (but not done) | 16 (18.2) | 13 (39.4) | 0.030 | 24 (5.8) | 17 (65.4) | < 0.001 |
| Central intravenous catheter | 28 (31.8) | 12 (36.4) | 0.670 | 8 (1.9) | 1 (3.8) | 0.430 |
| Past history of infective endocarditis | 1 (1.1) | 3 (9.1) | 0.060 | 29 (7.0) | 2 (7.7) | 0.700 |
| Predisposing manipulation | ||||||
| Acupuncture or articular injection | 0 | 0 | NA | 17 (4.1) | 0 | 0.610 |
| Dental manipulation | 0 | 0 | NA | 24 (5.8) | 2 (7.7) | 0.660 |
| Endoscopy with procedure | 4 (4.5) | 0 | 0.570 | 1 (0.2) | 0 | 1.000 |
| TACE or liver biopsy | 1 (1.1) | 1 (3.0) | 0.470 | 2 (0.5) | 0 | 1.000 |
| Genitourinary manipulation | 3 (3.4) | 1 (3.0) | 1.000 | 2 (0.5) | 0 | 1.000 |
| Orthopedic prosthesis | 2 (2.3) | 0 | 1.000 | 1 (0.2) | 0 | 1.000 |
| Perivertebral area procedure | 2 (2.3) | 0 | 1.000 | 2 (0.5) | 0 | 1.000 |
| Intracardiac device (PPM, ICD) | 1 (1.1) | 0 | 1.000 | 1 (0.2) | 0 | 1.000 |
| Causative organism | ||||||
| Viridans group streptococci | 5 (5.7) | 3 (9.1) | 0.680 | 127 (30.8) | 1 (3.8) | 0.002 |
| | ||||||
| Methicillin-sensitive | 19 (21.6) | 0 | 0.002 | 59 (14.3) | 4 (15.4) | 0.780 |
| Methicillin-resistant | 17 (19.4) | 11 (33.3) | 0.150 | 17 (4.1) | 5 (19.2) | 0.006 |
| Enterococcus | 8 (9.1) | 7 (21.2) | 0.120 | 28 (6.8) | 3 (11.5) | 0.420 |
| Coagulase-negative | 10 (11.4) | 1 (3.0) | 0.290 | 18 (4.4) | 1 (3.8) | 1.000 |
| HACEK | 0 | 0 | NA | 7 (1.7) | 0 | 1.000 |
| Fungus | 2 (2.3) | 4 (12.1) | 0.046 | 1 (0.2) | 1 (3.8) | 0.120 |
| Other bacteria | 16 (18.2) | 4 (12.1) | 0.590 | 52 (12.6) | 3 (11.5) | 1.000 |
| Culture negative | 11 (12.8) | 4 (12.1) | 0.410 | 121 (29.3) | 8 (30.8) | 0.830 |
Values are presented as mean ± SD or number (%).
NIE, nosocomial infective endocarditis; CIE, community-acquired infective endocarditis; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; NA, not assessed; TACE, transcatheter arterial chemoembolization; PPM, permanent pacemaker; ICD, implantable cardioverter defibrillator; HACEK, Haemophilus parainfluenzae, Haemophilus aphrophilus, Aggregatibacter actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae.
Association between clinical characteristics and in-hospital death in patients with nosocomial infective endocarditis by multiple analysis
| Variable | Crude | Adjusted | ||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI)[ | |||
| Age | 1.03 (1.01–1.06) | 0.045 | 1.04 (1.01–1.07) | 0.037 |
| Male sex | 0.40 (0.17–0.90) | 0.028 | 0.42 (0.17–1.08) | 0.070 |
| Liver cirrhosis | 1.21 (0.35–4.24) | 0.770 | 2.80 (0.64–12.34) | 0.170 |
| Chemotherapy | 2.83 (1.21–6.61) | 0.016 | 3.89 (1.18–12.87) | 0.026 |
| Hemodialysis | 0.27 (0.06–1.24) | 0.090 | 0.36 (0.07–1.91) | 0.230 |
| Central intravenous catheter | 1.22 (0.53–2.83) | 0.640 | 0.82 (0.26–2.63) | 0.740 |
| On indication of cardiac surgery (but not done) | 2.93 (1.21–7.08) | 0.017 | 2.18 (0.81–5.88) | 0.120 |
| Fungus | 5.93 (1.03–34.09) | 0.046 | 4.43 (0.61–31.94) | 0.140 |
OR, odds ratio; CI, confidence interval.
Estimated by multiple linear regression analysis of the variables indicated in the table.
Association between clinical characteristics and in-hospital death in patients with community-acquired infective endocarditis by multiple analysis
| Variable | Crude | Adjusted | ||
|---|---|---|---|---|
| Crude OR (95% CI) | Adjusted OR (95% CI)[ | |||
| Age | 1.06 (1.03–1.09) | < 0.001 | 1.04 (1.01–1.07) | 0.012 |
| Male sex | 1.07 (0.46–2.45) | 0.880 | 1.09 (0.38–3.16) | 0.870 |
| Liver cirrhosis | 2.79 (0.59–13.15) | 0.200 | 1.13 (0.17–7.30) | 0.900 |
| On indication of cardiac surgery (but not done) | 30.62 (12.36–75.84) | < 0.001 | 29.83 (10.19–87.31) | < 0.001 |
| Viridans group streptococci | 0.09 (0.01–0.67) | 0.019 | 0.14 (0.01–1.16) | 0.070 |
| MRSA | 5.55 (1.87–16.49) | 0.002 | 9.58 (2.27–40.45) | 0.002 |
OR, odds ratio; CI, confidence interval; MRSA, methicillin-resistant Staphylococcus aureus.
Estimated by multiple linear regression analysis of the variables indicated in the table.